HeartBeam has enrolled the first patients in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The enrollment was conducted by Prof. Dr. Vladan Vukcevic at the University Clinical Center of Serbia in Belgrade, marking a significant milestone in generating clinical data needed to expand the system's indication beyond arrhythmia assessment.
The company's technology represents a potential breakthrough in cardiac care through its cable-free device capable of collecting ECG signals in three dimensions from non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever patients are located, delivering actionable heart intelligence directly to physicians who can identify cardiac health trends and acute conditions outside traditional medical facilities.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, with the 12-lead ECG synthesis software gaining clearance in December 2025. The company holds over 20 issued patents related to technology enablement, demonstrating substantial intellectual property protection for its innovations. Additional information about the company's developments is available in its newsroom at https://ibn.fm/BEAT.
The ALIGN-ACS study represents a critical step toward potentially transforming cardiac health management by enabling earlier detection of heart attacks through portable technology. For business leaders and technology executives, this development highlights the growing intersection of medical technology, artificial intelligence, and remote patient monitoring. The ability to detect cardiac events outside clinical settings could significantly reduce healthcare costs while improving patient outcomes through timely intervention.
Industry implications include potential disruption to traditional cardiac monitoring systems and emergency response protocols. The technology's portability and 3D ECG capabilities could create new markets for at-home cardiac monitoring and telemedicine applications. For investors and business strategists, HeartBeam's progress demonstrates how medical technology companies are leveraging FDA clearances and clinical studies to expand product indications and address broader healthcare challenges.
The forward-looking nature of this development is subject to various factors beyond management's control, including risks detailed in the company's SEC filings available at http://IBN.fm/Disclaimer. However, the successful enrollment of patients in the ALIGN-ACS study represents tangible progress toward validating the technology's expanded applications in cardiac care.
